Autoimmune diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease affect millions of people across the globe. Addressing this widespread impact, a leading biopharmaceutical company based in the US introduced a biosimilar to a commonly used monoclonal antibody. Recognizing the critical importance of diligent pharmacovigilance, AWINSA Life Sciences was selected as the strategic partner to oversee this initiative. In this case study, we explore our collaboration with the biopharmaceutical company, focusing on our strategic approaches to ensuring long-term patient safety . This partnership underscores our commitment to enhancing healthcare outcomes by supporting the safe and effective use of biosimilars in treating autoimmune diseases.
Copyright © 2024 AWINSA Life Sciences Pvt. Ltd. All rights reserved.
59 E,Shrewsbury Place
Princeton, NJ 08540
United States
E13/9 First floor, Vasant Vihar,
New Delhi 110057
Wilhelmina Druckerlaan 10,
6532 SR,
Nijmegen,
The Netherlands
Cerrada Ahuizotla 53,
Col. Santiago Ahuizotla,
Del. Azcapotzalco
CP.02750
Ciudad de México, México.
